MX2025002450A - Compuestos de pirazolopirimidina y su uso medico - Google Patents
Compuestos de pirazolopirimidina y su uso medicoInfo
- Publication number
- MX2025002450A MX2025002450A MX2025002450A MX2025002450A MX2025002450A MX 2025002450 A MX2025002450 A MX 2025002450A MX 2025002450 A MX2025002450 A MX 2025002450A MX 2025002450 A MX2025002450 A MX 2025002450A MX 2025002450 A MX2025002450 A MX 2025002450A
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutical use
- pyrazolopyrimidine compound
- compound
- formula
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Biophysics (AREA)
- Transplantation (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022135949 | 2022-08-29 | ||
| JP2023027426 | 2023-02-24 | ||
| PCT/JP2023/030980 WO2024048519A1 (ja) | 2022-08-29 | 2023-08-28 | ピラゾロピリミジン化合物及びその医薬用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2025002450A true MX2025002450A (es) | 2025-04-02 |
Family
ID=90099947
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2025002450A MX2025002450A (es) | 2022-08-29 | 2025-02-27 | Compuestos de pirazolopirimidina y su uso medico |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20250114361A1 (enExample) |
| EP (1) | EP4582428A1 (enExample) |
| JP (2) | JP7585409B2 (enExample) |
| KR (1) | KR20250056233A (enExample) |
| CN (1) | CN119790055A (enExample) |
| AR (1) | AR130318A1 (enExample) |
| AU (1) | AU2023334673A1 (enExample) |
| CL (1) | CL2025000495A1 (enExample) |
| CO (1) | CO2025002359A2 (enExample) |
| IL (1) | IL319000A (enExample) |
| MX (1) | MX2025002450A (enExample) |
| PE (1) | PE20251551A1 (enExample) |
| TW (1) | TW202416965A (enExample) |
| WO (1) | WO2024048519A1 (enExample) |
| ZA (1) | ZA202501724B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024177126A1 (ja) * | 2023-02-24 | 2024-08-29 | 日本たばこ産業株式会社 | ６－アルコキシピラゾロピリミジン化合物及びその医薬用途 |
| AR131919A1 (es) * | 2023-02-24 | 2025-05-14 | Japan Tobacco Inc | Compuestos sustituidos de pirazolopirimidina y su uso médico |
| AU2024255473A1 (en) | 2023-04-14 | 2025-10-16 | Takeda Pharmaceutical Company Limited | Pyrazolopyrimidine derivatives as inhibitors of nlrp3 |
| WO2025140708A1 (zh) * | 2023-12-31 | 2025-07-03 | 杭州百新生物医药科技有限公司 | 吡唑并嘧啶类化合物及其医药用途 |
| WO2025153532A1 (en) | 2024-01-16 | 2025-07-24 | NodThera Limited | Nlrp3 inhibitors and glp-1 agonists combination therapies |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021242505A1 (en) * | 2020-05-08 | 2021-12-02 | Halia Therapeutics, Inc. | Inhibitors of nek7 kinase |
| JP2023542205A (ja) * | 2020-09-24 | 2023-10-05 | ヤンセン ファーマシューティカ エヌ．ベー． | 新規化合物 |
| CN113549080B (zh) * | 2021-08-27 | 2023-05-16 | 中国医学科学院放射医学研究所 | 一类1,2,3-三氮唑并嘧啶类化合物、其制备方法和用途 |
| US20240287079A1 (en) * | 2021-08-31 | 2024-08-29 | Japan Tobacco Inc. | 6-aminopyrazolopyrimidine compound and pharmaceutical use thereof |
-
2023
- 2023-08-28 WO PCT/JP2023/030980 patent/WO2024048519A1/ja not_active Ceased
- 2023-08-28 TW TW112132370A patent/TW202416965A/zh unknown
- 2023-08-28 CN CN202380062735.4A patent/CN119790055A/zh active Pending
- 2023-08-28 US US18/705,065 patent/US20250114361A1/en active Pending
- 2023-08-28 IL IL319000A patent/IL319000A/en unknown
- 2023-08-28 PE PE2025000467A patent/PE20251551A1/es unknown
- 2023-08-28 AU AU2023334673A patent/AU2023334673A1/en active Pending
- 2023-08-28 KR KR1020257009740A patent/KR20250056233A/ko active Pending
- 2023-08-28 EP EP23860281.7A patent/EP4582428A1/en active Pending
- 2023-08-28 AR ARP230102274A patent/AR130318A1/es unknown
- 2023-08-28 JP JP2023137929A patent/JP7585409B2/ja active Active
-
2024
- 2024-11-06 JP JP2024194113A patent/JP2025013515A/ja active Pending
-
2025
- 2025-02-21 CL CL2025000495A patent/CL2025000495A1/es unknown
- 2025-02-25 ZA ZA2025/01724A patent/ZA202501724B/en unknown
- 2025-02-27 MX MX2025002450A patent/MX2025002450A/es unknown
- 2025-02-27 CO CONC2025/0002359A patent/CO2025002359A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA202501724B (en) | 2025-11-26 |
| CN119790055A (zh) | 2025-04-08 |
| PE20251551A1 (es) | 2025-06-05 |
| JP2025013515A (ja) | 2025-01-24 |
| IL319000A (en) | 2025-04-01 |
| AR130318A1 (es) | 2024-11-27 |
| WO2024048519A1 (ja) | 2024-03-07 |
| AU2023334673A1 (en) | 2025-03-27 |
| KR20250056233A (ko) | 2025-04-25 |
| JP7585409B2 (ja) | 2024-11-18 |
| CO2025002359A2 (es) | 2025-03-27 |
| EP4582428A1 (en) | 2025-07-09 |
| JP2024032686A (ja) | 2024-03-12 |
| TW202416965A (zh) | 2024-05-01 |
| US20250114361A1 (en) | 2025-04-10 |
| CL2025000495A1 (es) | 2025-06-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2025002450A (es) | Compuestos de pirazolopirimidina y su uso medico | |
| CO2024010774A2 (es) | Inhibidor del inflamosoma nlrp3 y uso del mismo | |
| BR112022022669A2 (pt) | Inibidores de nek7 quinase | |
| CR7583A (es) | Nueva sal formiato de o-desmetil venlafaxina | |
| CR8102A (es) | Derivados de pirazolo- quinazolina, procedimiento para preparacion y su uso como inhibidores de quinasa | |
| ECSP055738A (es) | PROCESO ENANTIOSELECTIVO PARA LA PREPARACIÓN DE AMBOS ENANTIÓMEROS DE 10,11-DIHIDRO-10-HIDROXI-5H-DIBENZ-[b,f]-AZEPIN-5-CARBOXAMIDA Y SUS NUEVAS FORMAS DE CRISTAL | |
| AR033423A1 (es) | Sales farmaceuticas constituidas de una sustancia activa farmaceutica y al menos un edulcorante, medicamentos que contienen estas sales y uso de estas sales para la preparacion de medicamentos | |
| BR112023019435A2 (pt) | Inibidores de nek7 | |
| AR045318A1 (es) | Composicion farmaceutica que contiene un inhibidor de histona deacetilasa | |
| DE602004017194D1 (de) | Pyridylpyrrol-derivate als wirksame kinase-hemmer | |
| UY27740A1 (es) | Nuevos compuestos | |
| ECSP088296A (es) | Compuestos terapéuticos | |
| BRPI0411900B8 (pt) | compostos e composições farmacêuticas compreendendo os mesmos | |
| CO2025011311A2 (es) | Compuestos sustituidos de pirazolopirimidina y su uso médico | |
| BRPI0415053A (pt) | inibidor de p-glicoproteìna, método para preparar o mesmo e composição farmacêutica que compreende o mesmo | |
| BR0209645A (pt) | Oxazolo- e furopirimidinas e seu uso como medicamentos | |
| CO2020003977A2 (es) | Compuesto de heteroarilo con contenido de nitrógeno, y su uso farmacéutico | |
| CL2020002199A1 (es) | Compuesto de anillo de metillactama y uso farmacéutico del mismo. | |
| WO2023020212A9 (zh) | Drd2抑制剂在制备治疗与肝脏纤维化有关的疾病的药物中的应用 | |
| BRPI0617655A2 (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, ou um isômero óptico do mesmo, uso de um composto, e, formulação farmacêutica | |
| BRPI0417609B8 (pt) | derivados de 3-ciano-quinolina com atividade antiproliferativa, seu processo de preparação e uso e composição farmacêutica que os compreende | |
| AR114270A1 (es) | Compuestos de 4-metildihidropirimidinona y su uso farmacéutico | |
| BR112022000155A2 (pt) | Composição inibidora da micromolécula pi4kiiia, seu método de preparação, e uso da mesma | |
| AR043327A1 (es) | Uso de inhibidores de quinurenina 3- hidroxilasa para el tratamiento de la diabetes | |
| BRPI0514724A (pt) | inibidores da enzima hiv integrase |